Delivery Order 75N93024D00002-75N93024F00002
- Not listed
- This is a firm fixed-price purchase order awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency within the U.S. Department of Health and Human Services, to Advarra, Inc. (doing business as Chesapeake IRB) for Clinical Conductor software and related option year renewal. The contract has a ceiling value of $143,340.00 and a period of performance through July 27, 2027, with an option year renewal through July 27, 2026. This award is not associated with a...
- The Defense Health Agency awarded a $12.4M firm fixed-price definitive contract to Aderas Inc. on September 3, 2025, for Electronic Institutional Review Board (EIRB) support services, with an ultimate completion date of September 2, 2030. The contract, which carries no set-aside designation, involves the renewal of Cayuse integrated Research Information Software (iRIS) enterprise software licenses and support services for the DoD-approved EIRB system—the enterprise platform responsible for...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awarded a $443,000 delivery order against the Nonclinical Services for Development of Interventional Agents indefinite-delivery/indefinite-quantity (IDIQ) multiple award contract to Curia Global Inc., doing business as Amri. This firm fixed price order is for non-clinical services and will be performed in Spain from September 14, 2022 through December...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $21.9 million cost-plus-award-fee delivery order to Leidos Biomedical Research Inc. for pre-clinical assessment services. The contract, which commenced on June 17, 2024, and extends through July 21, 2030, will be performed at the contractor's Frederick, Maryland facility. As a Federally Funded Research and Development Center (FFRDC) contractor, Leidos Biomedical Research Inc. brings extensive capabilities in biomedical...
- The Department of Health and Human Services National Institutes of Health Office of Logisitics and Acquisition Operations awarded a $2.37 million firm fixed price delivery order contract to Axle Informatics, LLC to provide specialized support for the NIH-wide Institutional Review Board system and program. The contract has a period of performance from September 2020 through December 2022 and will be performed in Bethesda, Maryland. No set aside designation or subcontractors were indicated. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $6.34 million to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business based in Bethesda, Maryland. This contract, awarded on March 31, 2023, with an ultimate completion date of March 30, 2030, supports regulatory operations and related services essential to NIAID's research mission. The contract employs a cost-plus-fixed-fee...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to SRI International, a non-profit research and development institute. The contract is for $1,023,969.00 to provide non-clinical services for the development of interventional agents for infectious diseases. The contract has a period of performance through April 30, 2025 and was awarded on August 30, 2024. This contract is a delivery order under a larger Indefinite...
- This is a $5,310,519.00 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to SRI International, a non-profit research institute, for nonclinical services to support the development of interventional agents for infectious diseases. The contract was issued under the "Nonclinical Services for Development of Interventional Agents" master IDIQ contract. The contract does not have a small business set-aside designation. SRI International has...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Charles River Laboratories, Inc. a $5.24M firm fixed price delivery order on September 30, 2025, for the preparation and characterization of five vaccine candidates. The work will be performed at Charles River's facility in Wilmington, Massachusetts, with an ultimate completion date of September 29, 2027. This delivery order was awarded without a set-aside designation, reflecting Charles River's competitive standing in...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a delivery order valued at approximately $25.3 million to Digital Infuzion, LLC for OCR Project Management, Data Safety Monitoring Board (DSMB), and CROMS-related support services under the broader Clinical Research Support Services (CRSS) program. This task order, issued on March 25, 2024, with an ultimate completion date of March 24, 2029, represents work to be performed in Rockville, Maryland. The contract...
- 75N93024D00002Indefinite Delivery Contract
- 75N93024D00002-75N93024F00002Delivery Order
Advarra, Inc., doing business as Chesapeake IRB, has been awarded a delivery order valued at $995,037 by the National Institute of Allergy and Infectious Diseases (NIAID) to serve as the Institutional Review Board (IRB) of record for select NIAID studies at U.S. domestic sites. The firm fixed-price contract, awarded on April 1, 2024, will extend through December 31, 2029, with performance to be conducted in Columbia, Maryland. This delivery order was issued without a set-aside designation, meaning Advarra competed for the award in the open market. Advarra is a specialized provider of IRB services with extensive experience supporting federal agencies, particularly within the Department of Health and Human Services, offering protocol review, study oversight, and human subjects protection compliance services. This delivery order falls under Advarra's larger Indefinite Delivery Contract (IDC) with NIAID, established on April 1, 2024, with a ceiling value of $13.999 million and performance through March 31, 2031. The parent IDC represents a significant long-term commitment from NIAID to leverage Advarra's expertise in managing complex, multi-site clinical research activities and ensuring federal compliance with human subjects protection regulations. Advarra's IRB services are critical to NIAID's mission of conducting ethical, federally compliant research on infectious diseases and allergies, supporting the agency's broader research portfolio across multiple therapeutic areas and study protocols.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00003 | Exercise an Option | $81.9k | 3/8/26 | |
| P00002 | Exercise an Option | $221.3k | 9/4/24 | |
| P00001 | Exercise an Option | $81.9k | 7/29/24 | |
| Not listed | Not listed | $81.9k | 3/28/24 |